WallStSmart

Becton Dickinson and Company (BDX)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 851% more annual revenue ($21.92B vs $2.31B). BDX leads profitability with a 8.0% profit margin vs -9.0%. BDX earns a higher WallStSmart Score of 63/100 (C+).

BDX

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 6.7Quality: 5.5
Piotroski: 6/9Altman Z: 1.49

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+25.4%)

Margin of Safety

+25.4%

Fair Value

$242.22

Current Price

$149.43

$92.79 discount

UndervaluedFair: $242.22Overvalued

Intrinsic value data unavailable for NTRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

NTRA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
39.8%10/10

Revenue surging 39.8% year-over-year

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

NTRA4 concerns · Avg: 2.8/10
Price/BookValuation
15.8x4/10

Trading at 15.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-14.3%2/10

ROE of -14.3% — below average capital efficiency

Profit MarginProfitability
-9.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.12 suggests the stock is reasonably priced for its growth.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

BDX profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.57 — expect wider price swings.

NTRA is growing revenue faster at 39.8% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (63/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?